Loading
A phase 2 trial of Anlotinib in non-small-cell lung cancer, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., now recruiting.
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC is a phase 2 interventional study registered as NCT07562581 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 48 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-06. Interventions recorded: luvometinib + anlotinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Fosun Pharmaceutical Industrial Development, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/